@article{145bfd4003ae4d81a2a8b980a65c102e,
title = "Great debate: lipid-lowering therapies should be guided by vascular imaging rather than by circulating biomarkers",
abstract = "Advantages of tailoring lipid lowering therapy with biomarkers versus imaging.",
keywords = "biomarkers, calcium score, CT angiography, Hs-CRP, imaging, Lipids, risk assesment, Troponin",
author = "Lale Tokgozoglu and Morrow, \{David A.\} and Nicholls, \{Stephen J.\}",
note = "Funding Information: Conflict of interest L.T. has received consulting fees from Abbott, Astra Zeneca, Amgen, Bayer, MSD, Mylan, Novartis, Sanofi, Novo Nordisk and Daiichi Sankyo and honoraria from Abbott, Amgen, Daiichi Sankyo, MSD, Mylan, Novartis, Novo Nordisk, Sanofi, Servier, Pfizer, Recordati. D.A.M. has received research grant support to Brigham and Women{\textquoteright}s Hospital from Abbott Laboratories, Amgen, Anthos Therapeutics, ARCA Biopharma, AstraZeneca, Bayer Healthcare, Eisai, Merck \& Co, Novartis, Pfizer, Regeneron, Roche Diagnostics, Siemens and consulting fees from Abbott Laboratories, ARCA Biopharma, Inflammatix, Merck \& Co, Novartis, Roche Diagnostics and had participation on a Data Safety Monitoring Board InCarda Therapeutics. S.N. has received grants from AstraZeneca, New Amsterdam Pharma, Amgen, Anthera, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron and LipoScience and consulting fees fromAstraZeneca, Amarin, Akcea, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion, Boehringer Ingelheim, Vaxxinity and Sequris. Publisher Copyright: {\textcopyright} The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.",
year = "2023",
month = jul,
day = "1",
doi = "10.1093/eurheartj/ehad275",
language = "English",
volume = "44",
pages = "2292--2304",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "25",
}